{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:14:08Z","timestamp":1780989248958,"version":"3.54.1"},"reference-count":104,"publisher":"Elsevier","isbn-type":[{"value":"9780443193507","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.apcsb.2024.02.004","type":"book-chapter","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T20:15:30Z","timestamp":1712434530000},"page":"249-292","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy guided precision medicine in solid tumors"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.apcsb.2024.02.004_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010038","article-title":"A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer","volume":"15","author":"Alasmari","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib3","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1080\/21645515.2015.1075106","article-title":"Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma","volume":"11","author":"Andersen","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib4","doi-asserted-by":"crossref","unstructured":"Barbacid, M. (2003). ras GENES. 56, 779\u2013827. https:\/\/doi.org\/101146\/annurev.bi56070187004023.","DOI":"10.1146\/annurev.biochem.56.1.779"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Science Advances"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib6","first-page":"127","article-title":"Artificial intelligence in cancer imaging: Clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib7","first-page":"127","article-title":"Artificial intelligence in cancer imaging: Clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: Results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836821","article-title":"Cancer neoantigens: Challenges and future directions for prediction, prioritization, and validation","volume":"12","author":"Borden","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","article-title":"Cancer\u2014A biological approach: III. Viruses associated with neoplastic conditions. IV. Practical applications","volume":"1","author":"Burnet","year":"1957","journal-title":"British Medical Journal"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib12","first-page":"137","article-title":"Aus der Sitzung der medicinischen Section vom 13 November 1867","volume":"5","author":"Busch","year":"1868","journal-title":"Berlin Klin Wochenschr"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/onc.2016.338","article-title":"Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer","volume":"36","author":"Castagnoli","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070902","article-title":"The d16HER2 splice variant: A friend or foe of HER2-positive cancers?","volume":"11","author":"Castagnoli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib1","doi-asserted-by":"crossref","unstructured":"Cellular and humoral aspects of the hypersensitive states: A symposium at the New York Academy of Medicine.\u00a0Journal of the American Medical Association, 170 (1959), 883. https:\/\/doi.org\/10.1001\/JAMA.1959.03010070123025.","DOI":"10.1001\/jama.1959.03010070123025"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T cell receptor\u2010based cancer immunotherapy: Emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/hum.2018.218","article-title":"CAR T cells generated using sleeping beauty transposon vectors and expanded with an EBV-transformed lymphoblastoid cell line display antitumor activity in vitro and in vivo","volume":"30","author":"Chicaybam","year":"2019","journal-title":"Human Gene Therapy"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: Dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"npj Precision Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib18","first-page":"375","article-title":"Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigosus","volume":"131","author":"Coley","year":"1906","journal-title":"The American Journal of the Medical Sciences"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1 resistant metastatic lung cancer: A phase I trial HHS Public Access","volume":"27","author":"Creelan","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib21","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","article-title":"Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance","volume":"2","author":"Denduluri","year":"2015","journal-title":"Genes Disease"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acc.2015.03.006","article-title":"Monitoring trastuzumab resistance and cardiotoxicity: A tale of personalized medicine","volume":"70","author":"Dokmanovic","year":"2015","journal-title":"Advances in Clinical Chemistry"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib24","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib25","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-21-0115","article-title":"T-cell receptor mimic antibodies for cancer immunotherapy","volume":"20","author":"Duan","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"European Journal of Immunology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01679","article-title":"Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy","volume":"8","author":"Efremova","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib28","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3389\/fimmu.2018.02012","article-title":"Increased risk for malignancies in 131 affected CTLA4 mutation carriers","volume":"9","author":"Egg","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib29","first-page":"273","article-title":"\u00dcber den jetzigen Stand der Karzinomforschung","volume":"5","author":"Ehrlich","year":"1909","journal-title":"Ned TijdschrGeneeskd"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0029-1196806","article-title":"Ueber die Z\u00fcchtung der Erysipelkokken auf k\u00fcnstlichem N\u00e4hrboden und ihre \u00dcbertragbarkeit auf den Menschen","volume":"8","author":"Fehleisen","year":"1882","journal-title":"Deutsche Medizinische Wochenschrift (1946)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib33","article-title":"Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma","volume":"12","author":"Fenton","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib34","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1158\/1078-0432.CCR-14-0854","article-title":"Molecular pathways: Targeting NRG1 fusions in lung cancer","volume":"21","author":"Fernandez-Cuesta","year":"2015","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib36","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib37","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1055-9965.EPI-20-0075","article-title":"Radiomics improves cancer screening and early detection","volume":"29","author":"Gillies","year":"2020","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"8","key":"10.1016\/bs.apcsb.2024.02.004_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrg.2016.67","article-title":"Computational genomics tools for dissecting tumour\u2013immune cell interactions","volume":"17","author":"Hackl","year":"2016","journal-title":"Nature Reviews Genetics 2016"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.compmedimag.2020.101820","article-title":"Deep learning powers cancer diagnosis in digital pathology","volume":"88","author":"He","year":"2021","journal-title":"Computerized Medical Imaging and Graphics: The Official Journal of the Computerized Medical Imaging Society"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/11317600-000000000-00000","article-title":"Monoclonal antibodies targeting vascular endothelial growth factor: Current status and future challenges in cancer therapy","volume":"23","author":"Hsu","year":"2009","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014Mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"The New England journal of medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib42","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-19-0452","article-title":"U3-1402, a novel HER3-targeting antibody\u2013drug conjugate, for the treatment of colorectal cancer","volume":"18","author":"Koganemaru","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082160","article-title":"Antibody-drug conjugates in solid tumor oncology: An effectiveness payday with a targeted payload","volume":"15","author":"Kondrashov","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib44","first-page":"297","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Advances in Immunology"},{"issue":"1979","key":"10.1016\/bs.apcsb.2024.02.004_bib45","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib46","article-title":"TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells","volume":"2","author":"Lim","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib47","first-page":"299","article-title":"Cancer and innate immune system interactions: Translational potentials for cancer immunotherapy","volume":"35","author":"Liu","year":"2012","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","article-title":"Increasing cure rates of solid tumors by immune checkpoint inhibitors","volume":"12","author":"Ma","year":"2023","journal-title":"Experimental Hematology & Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Molecular Cancer"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib84","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/cancers12082223","article-title":"Antibody-drug conjugates: A promising novel therapy for the treatment of ovarian cancer","volume":"12","author":"Manzano","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Research & Therapy"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib52","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","article-title":"Nimotuzumab: Beyond the EGFR signaling cascade inhibition","volume":"45","author":"Mazorra","year":"2018","journal-title":"Seminars in Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib54","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: A new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"The Journal of Urology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib56","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib58","first-page":"299","article-title":"Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules","volume":"2","author":"Nledermann","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib59","doi-asserted-by":"crossref","first-page":"2005.0010","DOI":"10.1038\/msb4100014","article-title":"A comprehensive pathway map of epidermal growth factor receptor signaling","volume":"1","author":"Oda","year":"2005","journal-title":"Molecular Systems Biology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib60","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"4682","key":"10.1016\/bs.apcsb.2024.02.004_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of Bacillus Calmette-Gu\u00e9rin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4030014","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"4","author":"Parslow","year":"2016","journal-title":"Biomedicines"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib63","article-title":"Introduction to antibody-drug conjugates","volume":"10","author":"Pettinato","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","article-title":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin","volume":"1","author":"Ramakrishnan","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib65","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: Focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib66","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells HHS public access","volume":"19","author":"Robbins","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib67","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1158\/0008-5472.CAN-07-0538","article-title":"A novel epidermal growth factor receptor inhibitor promotes apoptosis in non\u2013small cell lung cancer cells resistant to erlotinib","volume":"67","author":"Rouge","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of Margetuximab vs Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib69","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus Trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial","volume":"41","author":"Rugo","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib70","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib71","article-title":"Antibody-drug conjugates in prostate cancer: A systematic review","volume":"15","author":"Sardinha","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2008.12.003","article-title":"Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash","volume":"113","author":"Schilder","year":"2009","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib73","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib74","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2007.11.029","article-title":"Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A gynecologic oncology group study","volume":"108","author":"Secord","year":"2008","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib75","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: A novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Delivery"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib76","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3858\/emm.2011.43.10.063","article-title":"One target, different effects: A comparison of distinct therapeutic antibodies against the same targets","volume":"43","author":"Shim","year":"2011","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib77","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Current Oncology (Toronto, Ont.)"},{"issue":"Suppl. 1","key":"10.1016\/bs.apcsb.2024.02.004_bib78","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3747\/co.v17is1.614","article-title":"KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies","volume":"17","author":"Souli\u00e8res","year":"2010","journal-title":"Current Oncology (Toronto, Ont.)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib79","first-page":"1067","article-title":"In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2","volume":"79","author":"Spiess","year":"1987","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib80","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovic","year":"2019","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib81","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1126\/science.183.4124.534","article-title":"Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice","volume":"183","author":"Stutman","year":"1974","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/mabs.2.2.11360","article-title":"The VEGF family in cancer and antibody-based strategies for their inhibition","volume":"2","author":"Sullivan","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib83","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib85","unstructured":"The hybridoma revolution: An offshoot of basic research\u2014Milstein\u20141999\u2014BioEssays\u2014Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/(SICI)1521\u20131878(199911)21:11%3C966::AID-BIES9%3E3.0.CO;2-Z. Accessed 28.10.23."},{"key":"10.1016\/bs.apcsb.2024.02.004_bib86","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib87","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12929-017-0341-0","article-title":"Cancer immunotherapy by targeting immune checkpoints: Mechanism of T cell dysfunction in cancer immunity and new therapeutic targets","volume":"24","author":"Tsai","year":"2017","journal-title":"Journal of Biomedical Science"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib89","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"Van Der Bruggen","year":"1991","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib90","first-page":"499","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Van Der Stegen","year":"2015","journal-title":"Nature Reviews: Drug Discovery"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib91","first-page":"587","article-title":"An antigenic peptide produced by peptide splicing in the proteasome","volume":"304","author":"Vigneron","year":"2004","journal-title":"Science (1979)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib92","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1634\/theoncologist.2016-0377","article-title":"A phase I trial of the IGF-1R antibody ganitumab (AMG 479) in combination with everolimus (RAD001) and panitumumab in patients with advanced cancer","volume":"23","author":"Vlahovic","year":"2018","journal-title":"The Oncologist"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib93","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.21037\/tcr.2020.03.10","article-title":"EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Translational Cancer Research"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib94","first-page":"1444","article-title":"An antigen produced by splicing of noncontiguous peptides in the reverse order","volume":"313","author":"Warren","year":"2006","journal-title":"Science (1979)"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib95","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/1078-0432.CCR-07-1509","article-title":"Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies","volume":"14","author":"Weiner","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib96","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","article-title":"Applying artificial intelligence for cancer immunotherapy","volume":"11","author":"Xu","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"10","key":"10.1016\/bs.apcsb.2024.02.004_bib97","first-page":"1488","article-title":"Developing neoantigen-targeted T cell\u2013based treatments for solid tumors","volume":"25","author":"Yamamoto","year":"2019","journal-title":"Nature Medicine 2019"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib98","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/978-1-4899-5037-6_50","article-title":"Current approaches to the adoptive immunotherapy of cancer","volume":"233","author":"Yang","year":"1988","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib99","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1158\/2159-8290.CD-20-0442","article-title":"An in vivo KRAS allelic series reveals distinct phenotypes of common oncogenic variants","volume":"10","author":"Zafra","year":"2020","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-981-15-3266-5_9","article-title":"Functions of immune checkpoint molecules beyond immune evasion","volume":"1248","author":"Zhang","year":"2020","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib102","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Wang, X., & Chen, Y. (2023). HIGHLIGHTS Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer. https:\/\/doi.org\/10.1002\/mco2.322.","DOI":"10.1002\/mco2.322"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib103","article-title":"Antibody-drug conjugates: The clinical development in gastric cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.apcsb.2024.02.004_bib104","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000488087","article-title":"Anti-angiogenics: Current situation and future perspectives","volume":"41","author":"Zirlik","year":"2018","journal-title":"Oncology Research Treatment"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Immunology for Engineers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162324000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162324000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:10:17Z","timestamp":1753816217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162324000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443193507"],"references-count":104,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2024.02.004","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}